Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-205 mimic
- Development stage
- Preclinical
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
miR-205 mimic is a synthetic double-stranded RNA oligonucleotide designed to replicate the biological activity of endogenous microRNA-205 (miR-205). As a tumor-suppressive microRNA, miR-205 targets several oncogenic pathways, including those involving ZEB1, Ubc13, E2F1, VEGF, and PROX1. By downregulating these targets, the mimic inhibits epithelial-mesenchymal transition (EMT), reduces cell proliferation, and impairs migratory and invasive potential in various malignancies such as melanoma, breast cancer, glioma, and colorectal cancer. It has also been investigated as a radiosensitizer. Delivery is typically achieved through nanoliposome-encapsulated systems like DOPC nanoparticles in preclinical models.
- Other names
- microRNA-205 mimicmicroRNA205 mimicmicroRNA 205 mimichsa-miR-205 mimichsa-miR205 mimichsa-miR 205 mimic
02
Targets
ZEB1 (Zinc finger E-box-binding homeobox 1)VEGFA (Vascular endothelial growth factor A)Prospero homeobox protein 1 mRNA 3′ untranslated regionUbiquitin-conjugating enzyme E2 N mRNA 3′ untranslated regionE2F transcription factor 1 mRNA 3' untranslated region
Beyond the preview
Go deeper on miR-205 mimic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-205 mimic.